louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05679882: Effects of Natural Sounds on Attention Restoration Outdoors
Official title: Effects of Natural Sounds on Attention Restoration Outdoors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cognitive Fatigue
Mental Fatigue
Behavioral Performance
Heart Rate Variability
Positive and Negative Affect
Inhibition, Psychological
Working Memory
Perceived Restoration
Lead sponsor: Nanyang Technological University
Sponsor class: OTHER
Collaborators: name: National Research Foundation, Singapore
name: Ministry of National Development, Singapore
name: Housing and Development Board, Singapore
First posted: 2023-01-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to examine whether listening to natural sounds in a noisy outdoor environment compared to no natural sounds influences behavioural, cognitive, affective, and physiological markers.

Detailed description: The investigators hypothesize that listening to natural sounds has restorative effects on attention by supporting greater use of involuntary attention. This generates the prediction that exposure to natural sounds in the context of a noisy outdoor environment will have greater restorative effects on attention (i.e., physiological, affective, cognitive, and behavioural) as compared to the control group (exposed to environmental noise only). Individual differences (i.e., age, gender, caffeine and food intake, body mass index, skin temperature, noise sensitivity, sleep quality, baseline physiology and behavioural performance) will be examined and accounted for. Environmental factors (i.e., outdoor humidity, temperature, and noise) will also be accounted for.

Eligibility criteria: Inclusion Criteria:

* Singapore-based
* Non-clinical
* 18-35years

Exclusion Criteria:

* Individuals with hearing difficulties or failing to meet the minimal threshold for normal hearing
* Individuals with a history of ear, developmental, neurological, or psychiatric disorder

Primary outcomes:
measure: Reverse Corsi Task (Change)
timeFrame: baseline and up to 60 mins after sound intervention
measure: Go/NoGo Task (Change)
timeFrame: baseline and up to 60 mins after sound intervention
measure: Change in Heart Rate Variability
timeFrame: 1 day (during fatiguing task and sound intervention)
measure: Positive and Negative Affect Schedule - Expanded Form
timeFrame: up to 60 mins after sound intervention
measure: Fatigue State Questionnaire (Change)
timeFrame: baseline and up to 60 mins after sound intervention
Secondary outcomes:
measure: Perceived Restorativeness Soundscape Scale
timeFrame: up to 60 mins after sound intervention
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Cultural Science Innovations, Nanyang Technological University
Study officials:
References:
Clinical trial NCT06484582: Investigation of Musculoskeletal System Disorders Seen in Automotive Industry Workers
Official title: Investigation of Musculoskeletal System Disorders Seen in Automotive Industry Workers
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Work-related Illness
Work Injury
Lead sponsor: Uskudar University
Sponsor class: OTHER
First posted: 2024-07-03
Enrollment: 500
Sex: MALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: auto industry workers

Brief summary: The aim of this study is to examine the musculoskeletal disorders seen in automotive industry workers.

Detailed description: This study will be conducted as a face-to-face survey. Surveys will be created with Google Forms and will be filled out by the physiotherapist according to the participant's response.

Eligibility criteria: Inclusion Criteria:

* Being between the ages of 25-60
* Not having any psychological or neurological disorders
* Being able to communicate in Turkish (written, verbal)
* Being able to communicate cognitively adequately
* Working full-time
* Being employed in an automotive industry for at least 5 years

Exclusion Criteria:

* Being under 18 or over 60
* Working part-time
* Being employed in the same business for less than 5 years

Primary outcomes:
measure: Work Productivity & Activity Impairment Questionnaire - General Health
timeFrame: 1 week
measure: Pittsburgh Sleep Quality Survey
timeFrame: 1 week
measure: Disabilities of the Arm, Shoulder and Hand Questionnaire
timeFrame: 1 week
measure: Rapid Upper Limb Assessment
timeFrame: 1 week
measure: Nordic Extended Musculoskeletal Questionnaire
timeFrame: 1 week
measure: The McGill Pain Questionnaire
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Uskudar University
Study officials:
affiliation: Uskudar University
name: Sude Asya ALŞAN
role: STUDY_CHAIR
References:
citation: Eakin JM. Leaving it up to the workers: sociological perspective on the management of health and safety in small workplaces. Int J Health Serv. 1992;22(4):689-704. doi: 10.2190/DNV0-57VV-FJ7K-8KU5.
citation: Govaerts R, Tassignon B, Ghillebert J, Serrien B, De Bock S, Ampe T, El Makrini I, Vanderborght B, Meeusen R, De Pauw K. Prevalence and incidence of work-related musculoskeletal disorders in secondary industries of 21st century Europe: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2021 Aug 31;22(1):751. doi: 10.1186/s12891-021-04615-9.
citation: d'Errico A, Cardano M, Landriscina T, Marinacci C, Pasian S, Petrelli A, Costa G. Workplace stress and prescription of antidepressant medications: a prospective study on a sample of Italian workers. Int Arch Occup Environ Health. 2011 Apr;84(4):413-24. doi: 10.1007/s00420-010-0586-3. Epub 2010 Oct 16.
citation: da Costa BR, Vieira ER. Risk factors for work-related musculoskeletal disorders: A systematic review of recent longitudinal studies. Am J Ind Med. 2010 Mar;53(3):285-323. doi: 10.1002/ajim.20750.
Clinical trial NCT01330082: Adjunctive Photodynamic Therapy in the Treatment of Chronic Periodontitis
Official title: Efficacy of Adjunctive Photodynamic Therapy Using Light-emitting Diode in the Treatment of Chronic Periodontitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Chronic Periodontitis
Keywords: Photodynamic therapy
Light-emitting diode
toluidine blue
scaling and root planing
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-04-06
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized clinical trial is to clinically evaluate the effectiveness of the adjunctive use of photodynamic therapy (PDT) with an light-emitting diode (LED) light source in the treatment of chronic periodontitis.


Eligibility criteria: Inclusion Criteria:

1. clinically diagnosis of advanced chronic periodontitis with more than 3 mm clinical attachment loss
2. presence of at least two teeth with probing depth of 4 to 6 mm without furcation involvement in each quadrant
3. at least 16 remaining teeth
4. no periodontal treatment in the past 12 months
5. no evidence of systemic disease related to periodontal problems
6. no use of antibiotics for the past 6 months
7. No smoking more than 10 cigarettes per day
8. no addiction to any kind of drugs
9. no pregnancy

Primary outcomes:
measure: Probing pocket depth
timeFrame: Baseline, one month, three month
Secondary outcomes:
measure: Clinical attachment loss
timeFrame: Baseline, one month, three month
measure: Bleeding upon probing
timeFrame: Baseline, one month, three month
measure: plaque index
timeFrame: Baseline,before PDT procedure, one month, three month
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Tehran University of Medical Sciences
Study officials:
affiliation: Tehran University of Medical Sciences
name: Neda Moslemi, DDS,MS
role: STUDY_CHAIR
affiliation: Tehran University of Medical Sciences
name: Seyed Hossein Bassir, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00083382: Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Official title: UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Myeloma
Thalidomide
Pamidronate
Aredia
Bisphosphonate
Anti-Angiogenesis
Smoldering/Indolent Myeloma
Zometa
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2004-05-24
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any side effects.

Detailed description: Recently laboratory research found that thalidomide can inhibit the formation of new blood vessels that are necessary for the growth and spread of cancer. In order to grow and increase in size tumors require new blood vessels to supply them with the necessary blood to grow. If we can prevent these new blood vessels feeding the tumor from being formed by using thalidomide we might slow or stop the growth of the tumor. This concept is called "anti-angiogenesis" It is hoped that thalidomide will slow or stop the growth myeloma. However, it cannot be guaranteed that you will benefit if you take part in this study. The treatment you receive may even be harmful.

Eligibility criteria: Inclusion Criteria:

* Patients must have a diagnosis of Smoldering or Indolent myeloma
* All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines.

Exclusion Criteria:

* Prior bisphosphonate therapy within 30 days prior to study entry.
* Serum creatinine \> 5 mg/dl, ascites, or serum direct bilirubin \> 2.5 mg/dl.
* Prior plicamycin or calcitonin within 2 weeks of study entry.
* Severe cardiac disease, unstable thyroid disease, or epilepsy.
* Prior radiation therapy to \> 20% of the skeleton.

Primary outcomes:
measure: Best Response
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences/MIRT
state: Arkansas
Study officials:
affiliation: University of Arkansas
name: Bart Barlogie, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008 Oct 15;112(8):3122-5. doi: 10.1182/blood-2008-06-164228. Epub 2008 Jul 31.
Clinical trial NCT02730182: Effect of High Altitude Exposure, Acclimatization and Re-exposure on Postural Control in Lowlanders
Official title: Effect of High Altitude Exposure, Acclimatization and Re-exposure on Postural Control in Lowlanders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Effect of High Altitude
Keywords: postural control
high altitude
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2016-04-06
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Prospective interventional trial in lowlanders evaluating the effect of acute exposure, acclimatization and re-exposure to high altitude on postural control

Detailed description: Baseline measurements including the assessment of the center of pressure during 30s, the cerebral oxygen saturation and a sharpened Romberg test will be performed in Santiago de Chile, 520 m, over the course of 3 days. Participants will then travel by commercial airline (5 h flight) and by bus (3 h ride) to the base camp of the Atacama Large Millimeter/Submillimeter Array (ALMA) telescope station located at 2900 m near San Pedro de Atacama, northern Chile. Participants will stay there for the next 8 nights and they will be spend the days (6-8 h daily) at the telescope station at 5050 m while undergoing testing as described above at the first and the last day at 5050m. Daily transports from 2900 to 5050 m will be by car (1 h ride, one way). After the first 8 day altitude sojourn participants will return to the Santiago area (520 m) for a 6 day recovery period.

A second altitude sojourn with an identical schedule as the one described above and a final low altitude stay of 3 days will follow.

Eligibility criteria: Inclusion Criteria:

* born, raised and currently living \<800m
* No overnight stay at altitudes \>1500 m 4 weeks before the study

Exclusion Criteria:

* Previous altitude intolerance to altitude \<3000 m
* Pregnancy
* Health impairment, which requires regular treatment

Primary outcomes:
measure: Center of pressure path length measured by Wii-balance board
timeFrame: Low altitude sojourn at 520 m; first sojourn at 5050 m Day 2, 7; second sojourn at 5050 m Day 2, 7
Secondary outcomes:
measure: Cerebral tissue oxygen saturation measured by near infrared spectroscopy
timeFrame: Low altitude sojourn at 520 m; first sojourn at 5050 m Day 2, 7; second sojourn at 5050 m Day 2, 7
measure: Postural stability measured by sharpened Romberg-test and heel-to-toe walk
timeFrame: Low altitude sojourn at 520 m; first sojourn at 5050 m Day 2, 7; second sojourn at 5050 m Day 2, 7
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University of Zurich
Study officials:
affiliation: University of Zurich
name: Konrad E Bloch, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00631982: Invitro Maturation of Oocytes for Patients With Polycystic Ovaries
Official title: In Vitro Maturation of Oocytes for Patients With Polycystic Ovaries
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Polycystic Ovaries
Keywords: in vitro maturation oocytes
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-03-10
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In vitro maturation of oocytes after minimal gonadotropin stimulation in patients with polycystic ovaries, to prevent cases of ovarian hyperstimulation.


Eligibility criteria: Inclusion Criteria:

* Polycystic ovaries
* Needing IVF for fertility treatment

Exclusion Criteria:

* Age above 39

Primary outcomes:
measure: maturation rate,
timeFrame: 18 months
Secondary outcomes:
measure: Fertilization rate, pregnancy rate
timeFrame: 18 months
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: IVF and Infertility Unit, Assaf Harofeh Medical Center
Study officials:
References:
Clinical trial NCT03677882: A Brief Mind-Body Bridging Intervention for Suicidal Ideation
Official title: A Randomized Pilot Study of a Brief Mind-Body Bridging Intervention for Suicidal Ideation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Suicidal Ideation
Mind Body Bridging
Keywords: mind body bridging
mindfulness
suicidal ideation
suicide related behaviors
Lead sponsor: VA Salt Lake City Health Care System
Sponsor class: FED
Collaborators: name: Mind Body Bridging Charity
First posted: 2018-09-19
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine whether a Brief Mind-Body Bridging Intervention for Suicidal Ideation (MBB-SI) will result in short or longer-term reduction of psychological factors associated with suicidal ideation (SI) and/or suicide-related behaviors (SRB's) compared to Treatment as Usual (TAU).


Eligibility criteria: Inclusion Criteria:

* Subjects will be Veterans aged 18-80 admitted to Substance Abuse Residential Rehabilitation Treatment Program (SARRTP) with addictive disorders and/or co-occurring psychiatric disorder with suicide risk factors.

Exclusion Criteria:

* None

Primary outcomes:
measure: Change in frequency and/or intensity of suicidal ideation
timeFrame: Weekly during the intervention, one-month post-intervention, three months post-intervention, six months post-intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: George E. Wahlen Department of Veterans Affairs Medical Center
state: Utah
Study officials:
affiliation: VA Salt Lake City HCS
name: William Marchand, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05206682: Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
Official title: Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cesarean Section; Dehiscence
Keywords: Cesarean Section Scar Defect
Zoladex
vaginal repair
Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2022-01-25
Enrollment: 94
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: GnRH-a will be used to postpone period after vaginal repair for Cesarean Section Scar Defect（CSD） patients with adenomyosis which will be compared with CSD patients with adenomyosis who receive transvaginal surgery without GnRH-a, whether delayed period improving the CSD prognosis will be assessed.

Detailed description: Women with CSD complicated with adenomyosis will be enrolled in this study. They all will receive vaginal excision and suture of CSD and will be required to undergo examinations at 6-months after surgery.

Interventioned group will be subcutaneous injected of Leuprorelin to postpone period after vaginal repair. It is be assumed that temporary menopause could improve inner conditions of uterus, there would be less local inflammation reaction which would be beneficial to the scar healed.

Eligibility criteria: Inclusion Criteria:

1. Clearly diagnosed with CSD complicated with adenomyosis
2. Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days).
3. The thickness of the remaining muscular layer of CSD was less than 3 mm.
4. Normal range of blood sugar and insulin
5. No serious medical problems (important viscera function in the normal range).
6. uterine fibroids no more than 5cm
7. Sign the informed consent.

Exclusion Criteria:

1. Indefinite diagnosis.
2. Malignant tumors.
3. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs).
4. Pregnant.
5. Mental diseases.
6. Allergy to the any ingredients of Leuprorelin
7. Unwilling to comply with the research plan.

Primary outcomes:
measure: thickness of the remaining muscular layer (TRM) (mm)
timeFrame: 12 weeks after vaginal repair of CSD
measure: Duration of menstruation (day)
timeFrame: 12 weeks after vaginal repair of CSD
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Jiaotong University xinhua hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT05373082: Identification of Modifying Factors in Hereditary Spastic Paraplegia
Official title: Identification of Modifying Factors in Hereditary Spastic Paraplegia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hereditary Spastic Paraplegia
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2022-05-13
Enrollment: 311
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Hereditary Spastic Paraplegia (HSP)

Brief summary: A first questionnaire - MODIFSPA conducted in 2014 - identified several environmental factors influencing spasticity in HSP: cold, fatigue, and especially physical activity. In order to improve the care of patients with HSP, The investigator team are looking to deepen the knowledge on physical exercises relieving spasticity as well as to better know the frequency of symptoms requiring additional medical care: fatigue and vesico-sphincter disorders. A new questionnaire was therefore created to collect additional information to optimize the care of patients with HSP.

Detailed description: The only common symptom of hereditary spastic paraplegia (HSP) is the presence of spasticity in the lower limbs, associated with a great clinical and genetic heterogeneity.

A first MODIFSPA study carried out by the team identified environmental factors influencing spasticity: stress, fatigue, physical activity. In this first study, only spasticity was studied but several symptoms appeared to require medical management according to the patients: fatigue and vesico-sphincter disorders.

Following this first study, MODIFSPA2 aims to deepen our knowledge of HSP, via the expertise of patients, to propose a care in adequacy with their needs/demands.

Validated scales are included in the questionnaire to evaluate the frequency and intensity of the symptoms most reported by patients (fatigue, pain and mood disorders). Questions are asked to better know the frequency of symptoms requiring additional medical care: fatigue and vesico-sphincter disorders.

Eligibility criteria: Inclusion Criteria:

* French-speaking adult patients aware of their PSH diagnosis coming to the genetic consultation at the Pitié-Salpêtrière Hospital or informed via an association / website of the BRAINTEAM study network
* Affiliated with social security

Exclusion Criteria:

* NA

Primary outcomes:
measure: factors influencing spasticity
timeFrame: 1 day
Secondary outcomes:
measure: Physical activities
timeFrame: 1 day
measure: Symptoms
timeFrame: 1 day
measure: Anxiety
timeFrame: 1 day
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut du Cerveau, ICM
Study officials:
References: